https://doi.org/10.18093/0869-0189-2012-0-6-96-102
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
About the Authors
S. N. Avdeev
ФГБУ "НИИ пульмонологии" ФМБА России
Russian Federation
Russian Federation
G. E. Baymakanova
ФГБУ "НИИ пульмонологии" ФМБА России
Russian Federation
Russian Federation
P. A. Zubairova
ФГБУ "НИИ пульмонологии" ФМБА России
Russian Federation
Russian Federation
References
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2011. www.goldcopd.org
2. Celli B.R., MacNee W. ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932-946.
3. Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
4. Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Morbid. Mortal. Wkly Rep. Surveill Summ. 2002; 51: 1-16.
5. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
6. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128-1138.
7. Stanford R.H., Shen Y., McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat. Respir. Med. 2006; 5: 343-349.
8. O'Donnell D.E., Parker C.M. COPD exacerbations: Pathophysiology. Thorax 2006; 61; 354-361.
9. Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
10. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 151: 1418-1422.
11. Miravitlles M., Murio C., Guerrero T. et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1455.
12. Celli B.R., Barnes P.J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29: 1224-1238.
13. Donaldson G.C., Hurst J.R., Smith C.J. et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091-1097.
14. Seneff M.G., Wagner D.P., Wagner R.P. et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. J.A.M.A. 1995; 274: 1852-1857.
15. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43-47.
16. Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). National Institute for Health and Clinical Excellence. www.nice.org.uk
17. Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir. Care 2007; 52: 1176-1193.
18. Hogg J.C., Chu F.S., Tan W.C. et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am. J. Respir. Crit. Care Med. 2007; 176: 454-459.
19. Rogers D.F., Barnes P.J. Treatment of airway mucus hypersecretion. Ann. Med. 2006; 38: 116-125.
20. Hogg J.C., Chu F., Utokaparch S. et al. The nature of smallairway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645-2653.
21. James A.L., Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur. Respir. J. 2007; 30: 134-155.
22. Macklem P.T., Proctor D.F., Hogg J.C. The stability of peripheral airways. Respir. Physiol. 1970; 8: 191-203.
23. Poole P.J., Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Br. Med. J. 2001; 322: 1271-1274.
24. Poole P., Black P.N. Mucolytic agents for chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 19 (3): JulCD001287.
25. Zuin R., Palamidese A., Negrin R. et al. High dose N-Acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin. Drug Invest. 2005; 25: 401-408.
26. Farkhutdinov U.R., Farkhutdinov R.R., Petryakov V.V. i dr. Vliyanie mukoliticheskoi terapii na produktsiyu aktivnykh form kisloroda v krovi u bol'nykh s obostreniem khronicheskoi obstruktivnoi bolezni legkikh. Ter. arkh. 2010; 3: 29-32.
27. Marchioni C.F., Polu J.M., Taytard A. et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharmacol. Ther. 1995; 33: 612-618.
28. Davies L., Calverley P.M.A. The evidence for the use of oral mucolytic agents in chronic obstructive pulmonary disease (COPD). Br. Med. Bull. 2010; 93: 217-227.
29. Hooper C., Calvert J. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Intern. J. COPD 2008; 3: 659-669.
30. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.
31. Borg G. Psychophysical bases of perceived exertion. Med. Sci. Sports Exerc. 1982; 14: 377-381.
32. Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 1993; 6 (Suppl. 16): 5-40.
33. Vestbo J. Epidemiological studies in mucus hypersecretion. In: Chadwick D.J., Goode J.A., eds. Novartis foundation symposium 248: Mucus hypersecration in respiratory disease. Malden: Wiley; 2002. 277-282.
34. Avdeev S.N. Znachenie mukoaktivnykh preparatov v terapii khronicheskoi obstruktivnoi bolezni legkikh. Pul'monologiya 2011; 4: 118-124.
35. Havez R., Degand P., Roussel P. et al. Biochemical mechanism of action of cysteine derivatives on bronchial mucus. Poumon 1977; 26: 81-90.
36. Puchelle E., Aug F., Polu J.M. Effect of the mucoregulator s-carboxymethyl-cysteine in patients with chronic bronchitis. Eur. J. Clin. Pharmacol. 1978; 14: 177-184.
37. Colombo B., Turconi P., Daffonchino L. et al. Stimulation of Cl- secretion by the mucoactive drug S-carboxymethylcysteine lysine - salt in the isolated rabbit trachea. Eur. Respir. J. 1994; 7: 1622-1628.
38. Asti C., Melillo G., Caselli G.F. et al. Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness. Pharmacol. Res. 1995; 31: 387-392.
39. Carpagnano G.E., Resta O., Foschino4Barbaro M.P. et al. Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur. J. Pharmacol. 2004; 505: 169-175.
40. Pinamonti S., Venturoli L., Leis M. et al. Antioxidant activity of carbocysteine lysine salt monohydrate. Panminerva Med. 2001; 43: 215-220.
41. Brandolini L., Allegretti M., Berdini V. et al. Carbocysteine lysine salt monohydrate (SCMC-Lys) is a selective scavenger of reactive oxygen intermediates (ROIs). Eur. Cytokine Netw. 2003; 14: 20-26.
42. Yasuda H., Yamaya M., Sasaki T. et al. Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur. Respir. J. 2006; 28: 51-58.
43. Asada M., Yoshida M., Hatachi Y. et al. L-carbocisteine inhibits respiratory syncytial virus infection in human tracheal epithelial cells. Respir. Physiol. Neurobiol. 2012; 180: 112-118.
44. Zheng C.H., Ahmed K., Rikitomi N. et al. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol. and Immunol. 1999; 43: 107-113.
45. Cakan G., Turkoz M., Turan T. et al. S-carboxymethylcysteine inhibits the attachment of streptococcus pneumonia to human pharyngeal epithelial cells. Microbial Pathogenes. 2003; 34: 261-265.
46. Braga P.C., Scaglione F., Scarpazza G. et al. Comparison between penetration of amoxicillin combined with carbocysteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue. Int. J. Clin. Pharm. Res. 1985; 5: 331-340.
47. Katayama N., Fujimura M., Ueda A. et al. Effects of carbocysteine on antigen-induced increases in cough sensitivity and bronchial responsiveness in guinea pigs. J. Pharmacol. Exp. Ther. 2001; 297: 975-980.
48. Ischiura Y., Fujimura M., Yamamori C. et al. Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients. Br. J. Clin. Pharmacol. 2003; 55: 504-510.
49. Allegra L., Cordaro C., Grassi C. Prevention of acute exacer- bations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: A multicentre, double-blind, placebo-controlled trial. Respiration 1996; 63: 174-180.
50. Zheng J.P., Kang J., Huang S.G. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet 2008; 371: 2013-2018.
51. Yasuda H., Yamaya M., Sasaki T. et al. Carbocysteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 2006; 54: 378-380.
52. Tatsumi K. Carbocysteine improves quality of life in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 2007; 55: 1884-1887.
Review
For citations:
Avdeev S.N., Baymakanova G.E., Zubairova P.A. . PULMONOLOGIYA. 2012;(6):96-102. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-6-96-102
Views:
1384
ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)
ISSN 2541-9617 (Online)
Email this article 